Risk factors associated with multiple organ damage in childhood<bold>-</bold>onset systemic lupus erythematosus

被引:1
作者
Puengpipattrakul, Thanaporn [1 ]
Lerkvaleekul, Butsabong [2 ]
Pirojsakul, Kwanchai [3 ]
Vilaiyuk, Soamarat [2 ]
机构
[1] Mahidol Univ, Fac Med, Dept Pediat, Ramathibodi Hosp, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pediat, Div Rheumatol,Ramathibodi Hosp, Bangkok, Thailand
[3] Mahidol Univ, Fac Med, Dept Pediat, Div Nephrol,Ramathibodi Hosp, Bangkok, Thailand
来源
FRONTIERS IN PEDIATRICS | 2023年 / 11卷
关键词
disease damage; connective tissue disease; pediatric; infection; disease activity; ocular; predictors; SLE; 3; ETHNIC-GROUPS; DISEASE-ACTIVITY; COHORT; COLLEGE; INDEX; SLE; CLASSIFICATION; FEATURES; LUMINA; VALIDATION;
D O I
10.3389/fped.2023.1301201
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective:Previous studies have shown that approximately 39%-65% of patientswith childhood-onset systemic lupus erythematosus (cSLE) have damage in atleast one organ. Data on risk factors for organ damage in cSLE remain limited,especially in Asian populations. This study was conducted to evaluate the incidence of cSLE and identify the risk factors for accumulated organ damage inpatients with cSLE. Methods:This was a retrospective study. Patients aged <18 years who were diagnosed with cSLE between 2008 and 2020 were enrolled. Information onbaseline characteristics, treatment, and disease activity assessed using theSystemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) was collected from diagnosis until the most recent visits were reviewed from medical records. Disease damage was measured using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Results:A total of 134 patients with a mean age at diagnosis of 11.2 +/- 2.9 years were enrolled. The median duration of treatment was 4.7 (interquartile range 2.8-7.1)years. Forty patients (29.9%) had irreversible organ damage (SDI > 1) with an incidence rate of 5.7 events per 100 person-years. The most frequent type oforgan damage was ocular (11.1%), followed by musculoskeletal (8.9%) and neurological (7.4%). High disease activity at diagnosis (SLEDAI-2K >= 12) (odds ratio[OR] 3.19, 95% confidence interval [CI] 1.32-7.68), infection (OR 3.73, 95% CI1.60-8.67), and mycophenolate mofetil use (OR 3.62, 95% CI 1.45-9.03) were predictors of organ damage. The median time to disease damage in patients with SLEDAI-2K scores >= 12 at diagnosis was 6.5 years (95% CI 5.77-7.36;P= 0.004).Conclusion:Physicians should be aware of organ damage in patients with cSLE,particularly those with high disease activity at initial presentation, those who are receiving mycophenolate mofetil therapy, and those with an infection
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Early versus later onset childhood-onset systemic lupus erythematosus: Clinical features, treatment and outcome
    Hui-Yuen, J. S.
    Imundo, L. F.
    Avitabile, C.
    Kahn, P. J.
    Eichenfield, A. H.
    Levy, D. M.
    LUPUS, 2011, 20 (09) : 952 - 959
  • [32] Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus
    Brunner, Hermine I.
    Gulati, Gaurav
    Klein-Gitelman, Marisa S.
    Rouster-Stevens, Kelly A.
    Tucker, Lori
    Ardoin, Stacey P.
    Onel, Karen B.
    Mainville, Rylie
    Turnier, Jessica
    Aydin, Pinar Ozge Avar
    Witte, David
    Huang, Bin
    Bennett, Michael R.
    Devarajan, Prasad
    PEDIATRIC NEPHROLOGY, 2019, 34 (01) : 117 - 128
  • [33] Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients
    Harris, Julia G.
    Maletta, Kristyn I.
    Kuhn, Evelyn M.
    Olson, Judyann C.
    CLINICAL RHEUMATOLOGY, 2017, 36 (02) : 351 - 359
  • [34] Academic Outcomes in Childhood-Onset Systemic Lupus Erythematosus
    Zelko, Frank
    Beebe, Dean
    Baker, Aimee
    Nelson, Shannen M.
    Ali, Aisha
    Cedeno, Adlin
    Dina, Blair
    Klein-Gitelman, Marisa S.
    Ying, Jun
    Brunner, Hermine I.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (08) : 1167 - 1174
  • [35] 2019 ACR/EULAR classification criteria and therapy in predicting organ damage accrual in patients with childhood-onset systemic lupus erythematosus: A retrospective study over the last 29 years
    Kifer, Nastasia
    Sestan, Mario
    Frkovic, Marijan
    Kifer, Domagoj
    Kozmar, Ana
    Padjen, Ivan
    Potocki, Kristina
    Anic, Branimir
    Batinic, Drago
    Malcic, Ivan
    Jelusic, Marija
    LUPUS, 2022, 31 (07) : 828 - 836
  • [36] Excess weight and associated risk factors in patients with systemic lupus erythematosus
    Moura dos Santos, Fabiana de Miranda
    Borges, Mariane Curado
    Telles, Rosa Weiss
    Correia, Maria Isabel T. D.
    Duarte Lanna, Cristina Costa
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (03) : 681 - 688
  • [37] From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus
    Lim, Lily Siok Hoon
    Pullenayegum, Eleanor
    Feldman, Brian M.
    Lim, Lillian
    Gladman, Dafna D.
    Silverman, Earl D.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (05) : 750 - 757
  • [38] The Role of Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus
    Sestan, Mario
    Kifer, Nastasia
    Arsov, Todor
    Cook, Matthew
    Ellyard, Julia
    Vinuesa, Carola G.
    Jelusic, Marija
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (07) : 5981 - 6002
  • [39] Outcome of adult Saudi patients with childhood-onset systemic lupus erythematosus
    Al Hamzi, H.
    Alhaymouni, B.
    Al Shaikh, A.
    Al-Mayouf, S. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (06) : 984 - 988
  • [40] Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment
    Rua-Figueroa Fernandez de Larrinoa, Inigo
    Lozano, Maria J. Cuadrado
    Fernandez-Cid, Carlos Marras
    Cobo, Tatiana
    Salman Monte, Tarek C.
    Freire Gonzalez, Mercedes
    Hidalgo Bermejo, Francisco J.
    Roman Gutierrez, Carmen San
    Cortes-Hernandez, Josefina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (07) : 821 - 829